←Back to Expert Scholars
Translational Medicine / 转化医学Nivolumab Lung Cancer Trials
Hossein Borghaei
DO, MS
🏢Fox Chase Cancer Center🌐USA
Chief, Division of Thoracic Medical Oncology
80
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Hossein Borghaei led CheckMate-057 which established nivolumab as a second-line treatment for nonsquamous non-small cell lung cancer, one of the earliest checkpoint inhibitor approvals in thoracic oncology. He directs thoracic medical oncology at Fox Chase.
Share:
🧪Research Fields 研究领域
CheckMate-057
nivolumab NSCLC
second-line immunotherapy
lung cancer trials
immunotherapy biomarkers
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Hossein Borghaei 的研究动态
Follow Hossein Borghaei's research updates
留下邮箱，当我们发布与 Hossein Borghaei（Fox Chase Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment